#Pharma #Bourse Bayer enters into collaboration with Seattle Genetics for development of anticancer drugs http://t.co/3G8SxB7DVe
June 26, 2013
Publicité
/http%3A%2F%2Fwww.chemweek.com%2FAssets%2FImage%2Fminireg-logo.jpg){kind=logo}
Bayer says that its Bayer HealthCare subgroup has entered into a new antibody-drug conjugate (ADC) collaboration with biotechnology company Seattle Genetics (Bothell, WA). Bayer, under the deal, will get worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets.